首页 | 本学科首页   官方微博 | 高级检索  
     

沙美特罗替卡松粉吸入剂治疗50例中、重度儿童哮喘的疗效
引用本文:陈啸洪,夏云,董传昌,陈青春,林爱雪. 沙美特罗替卡松粉吸入剂治疗50例中、重度儿童哮喘的疗效[J]. 中国新药与临床杂志, 2004, 23(9): 575-578
作者姓名:陈啸洪  夏云  董传昌  陈青春  林爱雪
作者单位:1. 绍兴市人民医院,儿科,浙江,绍兴,312000
2. 绍兴大学医学院,浙江,绍兴,312000
摘    要:目的 :观察沙美特罗替卡松粉吸入剂在儿童中、重度哮喘治疗中的疗效、安全性。方法 :将 80例中、重度哮喘病儿分成沙美特罗替卡松粉吸入剂治疗组 (治疗组 )和氟替卡松治疗组 (对照组 )。治疗组 5 0例 ,5~ 11a给予沙美特罗替卡松粉吸入剂 5 0μg / 10 0 μg·次 - 1(沙美特罗 5 0 μg,氟替卡松10 0 μg) ,bid。 12~ 14a给予沙美特罗替卡松粉吸入剂 5 0 μg/ 2 5 0 μg·次 - 1,bid。氟替卡松治疗组(对照组 ) 30例 ,5~ 11a给予氟替卡松 12 5 μg·次 - 1,bid。 12~ 14a给予氟替卡松 2 5 0 μg·次 1,tid。2组均连用 6mo ,按需使用沙丁胺醇。结果 :2组平均早、晚最大呼气峰流速值 (PEFam ,PEFpm ) ,需使用沙丁胺醇的日数在 8wk内有显著差异 ,自我评价在 4wk内有显著差异 ,症状评分在 3mo内有显著差异。 2组各有 1例咽部不适 ,经处理后缓解。结论 :沙美特罗替卡松粉吸入剂在儿童中、重度哮喘治疗中具良好的有效性、安全性。

关 键 词:哮喘  儿童  药物疗法  沙美特罗  氟替卡松
文章编号:1007-7669(2004)09-0575-04

Therapeutic effect of salmeterol xinafoate and fluticasone propionate powder for inhalation in treatment of 50 moderate and severe asthma children
CHEN Xiao-hong,XIA Yun,DONG Chuan-chang,CHEN Qing-chun,LIN Ai-xue. Therapeutic effect of salmeterol xinafoate and fluticasone propionate powder for inhalation in treatment of 50 moderate and severe asthma children[J]. Chinese Journal of New Drugs and Clinical Remedies, 2004, 23(9): 575-578
Authors:CHEN Xiao-hong  XIA Yun  DONG Chuan-chang  CHEN Qing-chun  LIN Ai-xue
Affiliation:CHEN Xiao-hong1,XIA Yun2,DONG Chuan-chang1,CHEN Qing-chun1,LIN Ai-xue2
Abstract:AIM: To evaluate the clinical efficacy and safety of salmeterol xinafoate and fluticasone propionate in the treatment of moderate and severe asthma children. METHODS: Eighty sick children with moderate and severe asthma were randomly divided into two groups. These children in the treatment group (n=50) were given salmeterol xinafoate and fluticasone propionate, 50 μg/ 100 μg, bid in the patients aged 5 to 11 a and 50 μg/ 250 μg, bid in those aged 12 to 14 a, respectively. These children in the control group (n=30) were given fluticasone propionate (flixotide) 125 μg, bid in the patients aged 5 to 11 a and 250 μg in those aged 12 to 14 a, respectively. RESULTS: There was significant difference in PEFam, PEFpm and the days of using salbutamol after 8 wk treatment in two groups (P <0.05). Self-assessment in two groups had also significant difference after 4 wk treatment (P <0.05). Asthma symptom scores were improved significantly after 3 mo treatment (P< 0.05). Each group had one patient suffering pharynx malaise who recovered quickly after proper treatments. CONCLUSION: Salmeterol xinafoate and fluticasone propionate possesses good effectiveness, safety and well tolerance in the treatment of moderate and severe asthma children.
Keywords:asthma  child  drug therapy  salmeterol  fluticasone  
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号